Postpartum Acquired Hemophilia A in Two Women With Previously Undiagnosed Carrier Status for von Willebrand Disease Type 2N and Heterozygous p.R854Q Mutation.

Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia.

Case Report: Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time.

Inhibition of activated protein C anticoagulant function enhances coagulation but does not interrupt downstream mechanisms driving hemophilic arthropathy.

How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?

Managing heavy menstrual bleeding in adolescents with bleeding disorders: Outcomes from a pragmatic LMIC approach.

ABO blood group-mediated VWF kinetics associated with early phenotypic divergence in dizygotic twins with severe hemophilia A.

Gene Therapy for Hemophilia: Innovations, Milestones, and Future Prospects.

Therapeutic Plateletpheresis for Thrombocytosis: Critical Analytic Reviews and Original Multicenter Experience.

Investigation of kinesiophobia, physical activity, quality of life, depression and anxiety level in adult people with hemophilia: A frequency-matched case-control study.

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.

In Vitro Stability Study Supports the Use of Efmoroctocog Alfa and Rurioctocog Alfa Pegol for Continuous Infusion in Hemophilia A.

FIXa-triggered thrombin generation correlates with FVIII levels less than 1% in reconstituted plasma mimicking samples obtained from patients with severe hemophilia A.

Optimized AAVrh10 and Factor 9 vectors demonstrate improved phenotypic rescue in hemophilia B mice.

Delayed diagnosis of acquired hemophilia a complicating hepatocellular carcinoma: a rare case of hepatectomy following atezolizumab and bevacizumab therapy.

Preceding Infections and Coagulation Biomarkers in Early-Onset Cryptogenic Ischemic Stroke.

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well.

Acute recurrent appendicitis in a hemophiliac Nepalese girl: beyond just… avoidance of formidable cuts! - A case report.

New Methods for Activated Partial Thromboplastin Time -Based Clot Waveform Analysis: Normalization and Multi-Parameter Combination.

An analysis of attitudes toward gene therapy in people with severe hemophilia in Germany, a survey-based cross-sectional study.

[Long-term efficacy analysis of the individualized prophylaxis regimen in children with moderate or severe haemophilia A].

An International Survey on the Assessment of Screening and Treatment of Thrombosis Complications in Pediatrics (ASTRO-Kids): Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.

Sex Differences in Cancer-Associated Thrombosis.

Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous Females.

Genotype-Specific Postural Control Deficits in Hemophilia A: Insights from Center of Pressure Analysis Beyond Radiographic Arthropathy.

Activated Protein C and the Retina: From Physiology to Therapeutic Potential.

Psychosocial Outcomes and Quality of Life in Patients with Hemophilia a Without Inhibitors: The HemoLIFE Study.

Building a gene editing lexicon: a model for rare and inherited disorders.

Postviral Anti-PF4 Immunothrombosis in Children: A Narrative Review with Practical Guidance.

Balancing the benefits and risks of rebalancing coagulation in haemophilia.

Building safeguards for gene therapy in haemophilia.

Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.

Case Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies.

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

In Vitro Spiking Comparison of Coagulation Potential Between Emicizumab and Mim8 in Whole Blood and Plasma From a Single Patient With Severe Hemophilia A Receiving FVIII Prophylaxis and Warfarin.

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.

Persons with high Hemophilia Joint Health Scores have reduced functional range of motion during simulated sports activities.

[Acquired hemophilia A secondary to marginal zone lymphoma].

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Regional variations and trends in hemophilia prevalence: A global analysis with future projection.

Exploring Italian nursing staff in anticoagulation clinics: a cluster-based description of current practice, nurse self-efficacy, job satisfaction, and interprofessional collaboration.

Single Cell Analysis Reveals the Presence of Novel Intermediate Cells in Both Mice and Patients With Severe MASLD.

Monochorionic diamniotic twin brothers with severe hemophilia A: a case report.

Diagnostic challenges and perioperative management of a lateral cystic neck mass in an adult patient with hemophilia B: A case report.

Comprehensive Care for People With Hemophilia: A Dental Perspective From an Indian Scenario.

Acquired Hemostasis Disorders.

National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population.

Haemophilia Care in India: A Multicentre Cross-Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata.

Subclinical Cardiac Diseases and the Role of Extracellular Vesicles in Patients with Hemophilia A Treated on-Demand.

A Case of Acquired Hemophilia A Following Robot-Assisted Minimally Invasive Esophagectomy.

Platelet dense granule defect: experience in the French population.

A combinatorial CAAR-T cell strategy to eliminate factor VIII inhibitors in preclinical models of hemophilia A.

Enhanced Peripartum Hemostatic Management Does Not Decrease Postpartum Hemorrhage Incidence in Hemophilia Carriers: the Pregnancy and Inherited Bleeding Disorders study (PRIDES).

Artificial Intelligence for Automated Detection of Joint Bleeding via Ultrasound in Hemophilia: Advancing Standardization.

Ten-Year Trends in Haemophilia A Care in the East Mediterranean Region: Insights From WFH Annual Global Surveys (2014-2023).

Development of a Novel Hemophilia A Mouse Model to Study Emicizumab and Factor VIII Inhibitor Risk.

Effect of Recombinant Tissue-Type Plasminogen Activator on Peripheral Blood Mononuclear Cells of Patients With Alteplase-Associated Angioedema.

Kinesiophobia in Parents of Children with Haemophilia.

Glanzmann thrombasthenia presenting with upper gastrointestinal bleeding: a case series and review of the literature.

Identification of Missense Variants in the C-domains of Von Willebrand Factor that cause Gain-of-Function-Like Activity.

Discrepancies of results for post infusion levels of extended half-life factor VIII/IX concentrates - a cause of concern, awaiting for solution.

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders.

COVID-19-Associated Acquired Hemophilia A With an Exceptionally High Inhibitor Titer: A Case of Remission and Overwhelming Sepsis.

Optimizing pediatric ITP therapy: a real-world study on plasma concentration-guided eltrombopag dosing.

Measurement uncertainty of ISO 17511:2020 compliant and globally standardized PT/INR test results.

Immune Response Associated Hepatotoxicity in Hemophilia Gene Therapy: Mechanisms, Management, and Challenges.

Factor II and Factor V Deficiencies: Current Management, Care Gaps and Call to Action for Therapeutic Advances.

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience.

Implementing Shared Decision-Making in Haemophilia Care: Best Practice Recommendations From a Western European Multi-Stakeholder Delphi Process.

Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A.

Is marstacimab the next step in personalized and effective haemophilia management?

Advancing pilonidal disease care through pediatric endoscopic treatment (PEPSiT): early insights.

Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial.

Association of Patient-Reported Outcomes with Hemophilia A Inhibitor Status and Treatment Product Type.

From nothing to abundance for hemophilia with inhibitors.

Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort.

Two decades of prenatal diagnosis in hemophilia A and B: a systematic review of global trends and current practices.

Gut microbiome composition and function reflect socioeconomic deprivation.

Pathogen-Reduce Cryoprecipitate: An Overview of Method(s) in Pathogen Reduction, Transfusion-Transmitted Infection Risk, and Inventory Management Considerations.

D-Dimer levels during pregnancy and postpartum: non-applicability of regularly used cut-offs for diagnosis of suspected pulmonary embolism.

Understanding Treatment Care and Delays in Acquired Hemophilia A: A Population-Based Study From Nova Scotia, Canada.

Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.

Beyond a century of discovery: the global and persistent burden of underdiagnosis in von Willebrand disease.

Long-term doctor-patient communication: a patient‑reported perspective from a large Italian survey.

Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.

Health Related Quality of Life (HRQoL) and the Factors Affecting it in Children with Hemophilia.

Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels.

Exercise Programmes for People With Haemophilia: A Scoping Review.

Exploring gene editing as a potential therapeutic strategy for hemophilia.

Empowering People With Haemophilia: A Mobile Solution for Self-Management.

Burden of disease in adult patients with hereditary angioedema: results from a multinational survey.

An ultra-expansible chitosan-silk fibroin miniaturized sponge loaded with tranexamic acid modified gelatin for coagulation abnormalities.

GTH 2026: Connected Science - Advanced Solutions.

A Multifactorial Case of Acquired Hemophilia A.

Research Progress on Transitional Care for Hemophilia Patients from Pediatric to Adult Services: Focusing on Disease Severity and Care Continuity.

Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Recombinant FVIII Concentrates Show Distinct Stability Profiles During Heat Treatment Prior to Inhibitor Testing.

Thrombin Generation Assays: Possibilities and Limitations.

Immune Response Mechanisms in Haemophilia A.

Gene Therapy of Haemophilia: Current Status and Future Directions.

Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough.

Rare inherited autosomal bleeding disorders in women: sex-related bleeding, pregnancy and delivery. A narrative review.

Analytical performance of the Roche Elecsys TnT hs Gen 6 immunoassay.

Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A.

A chemiluminescent microfluidic thrombin generation assay for real-time monitoring in patient plasma.

MLDP-AS: an optimized next-generation sequencing assay for enhanced detection of technically challenging variants in expanded carrier screening.

Country-level prediction of blood type distribution in hemophilia A in support of factor VIII consumption.

Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.

Enhancing Hemophilia A Care Through Home-Based Prophylaxis: Real-World Outcomes of a National Patient Support Program in Mexico.

Burden of hereditary angioedema: results from a multinational survey of caregivers for adult and pediatric patients.

Postpartum acquired hemophilia presenting as compartment syndrome: a diagnostic challenge in the emergency department.

Integrative modeling to improve bleeding risk prediction in adult female hemophilia A carriers.

A Revised Classification of FVIII Concentrates: Rationale and Novel Metrics.

FVIII-containing platelets modulate immune responses and attenuate inhibitor development in hemophilia A mice.

The importance of data transformation in correlation analysis of factor VIII and inhibitor titers in acquired hemophilia.

The unforeseen consequence of smart bio-implants for hemophilia: chronic inflammation and antibody development.

QFitlia (Fitusiran): redefining hemophilia treatment with RNAi therapy. A correspondence.

Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3.

Research priorities for pediatric venous thromboembolism prevention: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.

Clinical Spectrum, Subtype Distribution, and Treatment Outcomes in von Willebrand Disease: A Prospective Study from a Hemophilia Treatment Center in Pakistan.

Rhein-modified hemodialysis membranes suppress red blood cell fatigue and thrombosis.

Mutations of six amino acid residues in a B domain-deleted blood coagulation factor VIII have a cumulative effect on increasing its secretion.

TNF‑α Gene Polymorphisms as Determinants of Alloantibody Emergence in Hemophilia: A Systematic Review and Meta-Analysis.

Factors contributing to the development of hemophilic arthropathy: A real-world study.

A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.

Monitoring the Hemostatic Balance: measuring thrombin generation in a patient with acquired hemophilia A on combined pro- and anticoagulant therapy.

rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation.

Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.

A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase I/II trials.

Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database.

Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells.

Vascular Disease Patient Information Page: Hereditary hemorrhagic telangiectasia (HHT).

Prevalence of hospital readmission, related causes and determinants in older people from 2010 to 2022.

Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors.

A Case Report on Emergency Medicine: Suspected Acquired Hemophilia A in an Older Adult Male.

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X.

Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.

Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay.

Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression.

Corrigendum to "Real-world safety and effectiveness of rurioctocog alfa pegol in 338 patients with hemophilia A in South Korea: A postmarketing surveillance study" [Thromb. Res. 253 (2025) 109402].

Towards a value-based approach in hemophilia: indications from the FAR-BENE study.

Evidence-based dental management strategies for individuals with congenital hemophilia: a systematic review.

Mild hemophilia B in a female with compound heterozygous FIX variants presented with abdominal pain and diagnosed with nutcracker syndrome, and median arcuate ligament syndrome.

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis.

Sleep and Haemophilia-A Case-Control Analysis of Associated Factors.

Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis.

Hemophilia Severity and Its Association With Mental Health and Health-Related Quality of Life-Results From a Cross-Sectional Multicenter Study.

Nine areas with outstanding challenges for hemophilia B research.

Coexistence of two X-linked disorders: hemophilia A and G6PD deficiency.

Complex Triple Deformity of the Knee Managed with Knee Arthrodesis in a Severe Hemophilia A Patient: A Case Report.

Treatment of canine hemophilia A via intraosseous delivery of a platelet-specific factor VIII-lentiviral vector.

Molecular Mechanisms of Factor IX Signal Peptide and Propeptide Mutations Underlying Hemophilia B.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Case Report: Intracranial hemophilic pseudotumor mimicking an aggressive neoplasm: a rare skull-invasive presentation.

Extraarticular and Intraarticular Key Lesions in Knee Joints of Adult Persons with Hemophilia-A Case-Control Ultrasound Study.

Acquired Hemophilia A After Neoadjuvant Immunotherapy for Renal Cell Carcinoma.

Building a Comprehensive Sickle Cell Disease Program in Western Kenya: A Decade of Experience and Growth.

Paediatric Subanalysis of TSUBASA, Assessing Physical Activity, Bleeding, Quality of Life and Safety in People with Haemophilia A Receiving Emicizumab.

Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis.

Key Findings From the World Federation of Haemophilia National Member Organization Survey on Women and Girls With Bleeding Disorders.

Clinical outcomes and health-system challenges in congenital afibrinogenemia: a single-centre prospective case series.

Refined target-mediated drug disposition modeling of the anti-tissue factor pathway inhibitor antibody MG1113 in cynomolgus monkeys and rabbits.

Transplanted gene-modified placental cells boost FVIII activity in pediatric sheep without eliciting immunity, toxicity, or adverse events.

Redefining hemophilia management: treatment goals, nonfactor replacement therapies, and the role of fitusiran.

Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies within the Takeda factor VIII portfolio.

Central retinal vein occlusion in hemophilia B: between bleeding and thrombosis.

Platelet function abnormalities in acquired hemophilia A.

Updated global prevalence and ethnic diversity of von Willebrand disease based on population genetics analysis.

The IL-33 receptor ST2 as a therapeutic target for hemophilic arthropathy.

Liver Transplantation for a Patient With Hemophilia and HIV/HCV Coinfection Complicated by Pulmonary Hypertension.

Acquired thrombotic thrombocytopenic purpura and HIV infection: a case report and review of the literature.

On Factor VIII Assay Discrepancies in Post-infusion Samples Obtained from Patients Treated with Efanesoctocog Alfa.

Factor VII deficiency is more prevalent than previously reported.

Malignancy and gene therapy in hemophilia.

Anti-emicizumab antibodies and their relevance in clinical practice.

Joint tissue plasticity in hemophilia: insights from the Joint Activity and Damage Exam ultrasound protocol.

Interfacility Collaboration for Hemophilia Care in Japan: A Retrospective Database Study Using a Japanese Healthcare Claims Database.

Balancing Promise and Peril: Hemophilia Gene Therapy Insights.

Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments.

Evaluation of the Burden of Bone Fractures in People Living With Haemophilia: A Registry-Based Matched Cohort Study.

Bridging the Gap: Efficacy of Low-Dose Emicizumab in Haemophilia A With or Without Inhibitors.

Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise.

Reassessing the Evidence and Opportunities Ahead for Pediatric Iron Deficiency Anemia.

Genetic predisposition and the role of homocysteine in a female with late diagnosis of autism.

An Initial Diagnosis of Acquired Hemophilia A in an Elderly Male With a Neck Hematoma.

Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice.

Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.

From Hip Effusion to Hemophilia: Unveiling the Cause of Pain in 6-Month-Old Infant. A Case Report.

IL-15 overexpression promotes memory program and anti-tumor activity of CD64 CAR T cells in a preclinical AML model.

How Do Muscles Protect Joints in Hemophilia? Integrating Mechanical, Neural, and Endocrine Mechanisms.

Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis.

Genetic regulation of fatty acid content in adipose tissue.

Performance of Factor VIII Extended Half-Life Product Measurements in External Quality Assessment Programmes.

Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study.